Advanced therapy medicinal products: current and future perspectives

Journal of Market Access and Health Policy

Volumn 4, Issue 1, 2016, Pages

  Hanna, Eve ^a,b   Rémuzat, Cécile ^b   Auquier, Pascal ^a   Toumi, Mondher ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b CREATIV CEUTICAL   (France)

Author keywords

advanced therapy medicinal products; ATMPs; clinical trials; market access

Indexed keywords

EID: 85164370727     PISSN: None     EISSN: 20016689     Source Type: Journal    
DOI: 10.3402/jmahp.v4.31036     Document Type: Article

References (34)

1. European Commission. Commission Directive 2009/120/EC of 14 September 2009 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use as regards advanced therapy medicinal products. Official Journal of the European Union 15.9. 2009. L242/3-12. 2009
2. Regulation (EC) No 1394/2007 of the European Parliament and of the council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 official journal of the European Union, 10/12/2007. Available from: http://ec.europa.eu/health/files/eudralex/vol-1/reg_2007_1394/reg_2007_1394_en.pdf [cited 1 July 2015].
3. European Medicines Agency, Committee for advanced therapies (CAT). Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000266.jsp [cited 1 July 2015].
4. Directive 2001/83/EC of the European Parliament and of the council of 6 November 2001 on the Community code relating to medicinal products for human use. JO L 311 du 28.11.2001, p. 67. Available from: http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_fr.pdf [cited 1 July 2015].
5. Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating patients with metastatic castration resistant prostate cancer: A comprehensive review of available therapies. J Urol. 2015; 194(6): 1537–47. [PubMed Abstract].
6. Watanabe N, Yano K, Tsuyuki K, Okano T, Yamato M. Re-examination of regulatory opinions in Europe: Possible contribution for the approval of the first gene therapy product Glybera. Mol Ther Methods Clin Dev. 2015; 2: 14066, doi: http://dx.doi.org/10.1038/mtm.2014.66 [PubMed CentralFull Text].
7. Vanlauwe J, Huylebroek J, Van Der Bauwhede J, Saris D, Veeckman G, Bobic V, etal. Clinical outcomes of characterized chondrocyte implantation. Cartilage. 2012; 3(2): 173–80. [PubMed Abstract] [PubMed CentralFull Text].
8. ®) grafts in an equine model at 53 weeks. J Biomech. 2015; 48(10): 1944–9. [PubMed Abstract].
9. European Medicines Agency. EPAR summary for the public, Holoclar EMA/6865/2015, 2/2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002450/WC500183406.pdf [cited 1 July 2015].
10. European Medicines Agency. Closure of EU manufacturing site for MACI. 2014. EMA/733307/2014, 19/11/2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Maci_20/WC500173680.pdf [cited 1 July 2015].
11. European Medicines Agency. Provenge, Withdrawal of the marketing authorisation in the European Union. EMA/303072/2015, 11/5/2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2015/05/WC500186950.pdf [cited 1 July 2015].
12. ®)–Autopsy of an innovative paradigm change in cancer treatment: Why a single-product Biotech company failed to capitalize on its breakthrough Invention. Bio Drugs. 2015; 29(5):301–7.
13. Rehmann W, Morgan G. The regulation of advanced therapies: Perspectives from the EU. 2009.; RAJ Pharma.Available from: http://united-kingdom.taylorwessing.com/uploads/tx_siruplawyermanagement/The_Regulation_of_Advanced_Therapies.pdf [cited 2 July 2015].
14. Thanner M, Nagel E. A comprehensive assessment of ATMP. Difficulties and approaches. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2011; 54(7): 843–8. doi: http://dx.doi.org/10.1007/s00103-011-1300-7 [PubMed Abstract].
15. Maciulaitis R, D'Apote L, Buchanan A, Pioppo L, Schneider CK. Clinical development of advanced therapy medicinal products in Europe: Evidence that regulators must be proactive. Mol Ther. 2012; 20(3): 479–82. [PubMed Abstract] [PubMed CentralFull Text].
16. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012–An update. J Gene Med. 2013; 15: 65–77. doi: http://dx.doi.org/10.1002/jgm.2698 [PubMed Abstract].
17. Trouson A, Mc Donald C. Stem cell therapies in clinical trials: Progress and challenges. Cell Stem Cell. 2015; 17(1): 11–22. doi: http://dx.doi.org/10.1016/j.stem.2015.06.007.
18. Bisson I, Green E, Sharpe M, Herbert C, Hyllner J, Mount N. Landscape of current and emerging cell therapy clinical trials in the UK: Current status, comparison to global trends and future perspectives. Regen Med. 2015; 10(2): 169–179. doi: http://dx.doi.org/10.2217/rme.14.71 [PubMed Abstract].
19. Sanzenbacher R, Dwenger A, Schuessler-Lenz M, Cichutek K, Flory E. European regulation tackles tissue-engineering. Nat Biotechnol. 2007; 25: 1089–91. [PubMed Abstract].
20. Hanna E, Tavella F, Rémuzat C, Auquier P, Toumi M. Market access of ATMPs: Overview and expected challenges. Value Health. 2015; 18(7): A518–19. [PubMed Abstract].
21. Chouaid C, Borget I, Braun E, Bazil M, Schaetz D, Rémuzat C, etal. French health technology assessment of antineoplastic drugs indicated in the treatment of solid tumours: Perspective for future trends. Value Health. 2016; 18(7):A489.
22. European Medicines Agency recommends 39 medicines for human use for marketing authorisation in first half of 2014. 2014; London: European Medicines Agency.Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/07/news_detail_002135.jsp&mid=WC0b01ac058004d5c1 [cited 14 December 2015].
23. Cylus J, Mladovsky P, McKee M. Is there a statistical relationship between economic crises and changes in government health expenditure growth? An analysis of twenty-four European countries. Health Serv Res. 2012; 47(6): 2204–24. [PubMed Abstract] [PubMed CentralFull Text].
24. Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007; 23(1): 36–42. [PubMed Abstract].
25. Morrison C. $1-million price tag set for Glybera gene therapy. Nat Biotechnol. 2015; 33(3): 217–8. [PubMed Abstract].
26. ® (Wirkstoff: Alipogentiparvovec) wegen einer erneuten Befassung der EMA mit dem Wirkstoff vorläufig ausgesetzt, Berlin, 16/04/2015. Available from: https://www.g-ba.de/institution/presse/pressemitteilungen/572/ [cited 3 July 2015].
27. Siddiqui M, Rajkumar SV. The high cost of cancer drugs and what we can do about it. Mayo Clin Proc. 2012; 87(10): 935–43. doi: http://dx.doi.org/10.1016/j.mayocp.2012.07.007 [PubMed Abstract] [PubMed CentralFull Text].
28. Institute for Quality and Efficiency in Health Care (IQWIG). Sipuleucel-T in prostate cancer: Indication of added benefit. 2015. Available from: https://www.iqwig.de/en/press/press-releases/press-releases/sipuleucel-t-in-prostate-cancer-indication-of-added-benefit.6618.html [cited 3 July 2015].
29. National Institute for Health and Care Excellence (NICE). Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer. NICE technology appraisal guidance [TA332]. 2015. Available from: https://www.nice.org.uk/guidance/ta332 [cited 3 July 2015].
30. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: A population-based cost analysis. Lancet Oncol. 2013; 14: 1165–74. [PubMed Abstract].
31. ESMO 2012 Press release: The true costs of cancer in Europe revealed. Vienna: Austria; 2012. Available from: http://www.esmo.org/Conferences/Past-Conferences/ESMO-2012-Congress/News-Press-Releases/ESMO-2012-Press-Releases/The-true-costs-of-cancer-in-Europe-revealed [cited 15 September 2015].
32. WHO. Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research. 2015. Available from: http://apps.who.int/medicinedocs/documents/s21793en/s21793en.pdf [cited 15 September 2015].
33. Anastasaki E, Bradshaw SE, Walker A. An update on market access for advanced therapy medicinal products in Europe. 2014; Amsterdam: ISPOR.
34. Lee D, Hanna E, El Hammi E, Rémuzat C, Toumi M. Sofosbuvir: The failure of pricing policies in the European Union. Poster presented at International Society for Pharmacoeconomics and Research Outcomes 18th Congress, Milan, Italy, November 2015.